Tschan, Viviane J.
Borgna, Francesca
Schibli, Roger
Müller, Cristina http://orcid.org/0000-0001-9357-9688
Funding for this research was provided by:
Personalized Health and Related Technologies PHRT (PHRT-301)
European Union’s Horizon 2020 research and innovation program (701647)
Swiss Cancer Research Foundation (KFS-4678-02-2019-R)
Article History
Received: 19 March 2021
Accepted: 2 June 2021
First Online: 17 August 2021
Change Date: 13 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: This study was performed in agreement with the national law and PSI-internal guidelines of radiation safety protection. In vivo experiments were approved by the local veterinarian department and ethics committee and conducted in accordance with the Swiss law of animal protection.
: The authors declare that the following competing financial interest(s): patent applications on PSMA ligands with albumin-binding entities have been filed by Medical Isotopes ITM GmbH, Germany.